Skip to content

Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-Ag

Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7 Antigen

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01366586
Enrollment
5
Registered
2011-06-06
Start date
2011-05-31
Completion date
2011-07-31
Last updated
2011-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

The study aims to: 1. Achieve molecular imaging of MG7 antigen in patients with gastric cancer in vivo using confocal laser endomicroscopy. 2. Compare the results of in vivo MG7-specific molecular imaging with CLE and ex vivo immunohistochemistry .

Detailed description

Gastric cancer remains the world's second leading cause of cancer-related death. Improved prognosis essentially depend on earlier diagnosis. Gastric monoclonal antibody MG7 has been validated as a specific antibody in gastric cancerous tissue. Conventional evaluation of MG7 antigen expression is immunohistochemistry, which is time-consuming, and the immunoreactivity can be affected by storage and fixation of tissue. Confocal laser endomicrosopy enables visualization of the cellular and subcellular structures in vivo. Thus this study aims to achieve molecular imaging of MG7 antigen in gastric cancer in vivo using confocal laser endomicroscopy.

Interventions

None listed

Sponsors

Shandong University
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patients with endoscopically diagnosed gastric cancer

Exclusion criteria

* Patients who are allergic to fluorescein sodium * Patients who are unwilling to sign or give the informed consent form * Patients with giant tumors or obvious GI tract bleeding which make it hard or impossible to observe the lesions * Patients with impaired cardiac, liver or renal function * Patients with coagulopathy * Patients with pregnancy or breastfeeding

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026